FusionPlex® Lung v2

The FusionPlex® Lung v2 panel is a targeted Next-Generation Sequencing (NGS) research product that expands on the well-adopted FusionPlex® Lung panel to further drive discovery. The updated design covers newly published fusion breakpoints and isoforms of interest in key gene targets (including the NTRKs) and aligns with existing guidelines for non-small cell lung cancer research, including NCCN and ESMO (ESCAT).

FusionPlex® uses RNA instead of DNA as input material, which allows for more accurate and more cost-effective fusion detection than DNA-based hybrid capture techniques. FusionPlex® places gene-specific primers near known fusion breakpoints to identify RNA abnormalities with a single primer. Because FusionPlex® can identify known and novel alterations with a limited number of primers, it can detect fusions more efficiently and accurately than DNA-based approaches.

All gene content from the Lung v1 panel is covered in v2, including EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations.

The panel is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.

Archer Analysis software allows the analysis and interpretation of the data.

Comprehensive Fusion Detection

AMP™ chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.

Splice Variant

Detect cancer-associated isoforms and alternative splicing events.

Low Input

Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.

Simple Workflow, Lyophilized Reagents

Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turn-around time.